Peptides are short chains of amino acids — the same building blocks that make up proteins — that act as biological signaling molecules in the body. They regulate a remarkable range of functions including hormone secretion, appetite, tissue repair, inflammation, and immune modulation. In medicine, synthetic peptides are used to mimic, amplify, or modulate these natural signals in targeted ways.

Are therapeutic peptides FDA-approved?

It depends on the specific peptide and indication. GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved for diabetes and obesity. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Many other peptides explored in telehealth settings — including BPC-157 and TB-500 — are not FDA-approved for any indication and are not on the 503A compounding bulks list as of May 2026. Regulatory status is stated explicitly on each compound page.

How does YourHealthRx evaluate evidence for each peptide?

We use a standard hierarchy: Level I evidence (multi-center RCTs and meta-analyses) carries the most weight, followed by Level II (single RCTs, controlled studies), Level III (cohort and case-control studies), and Level IV-V (case series, preclinical animal studies, expert opinion). Evidence level is stated for every compound. Where evidence is only preclinical, we say so clearly.

How do you decide what's safe enough to discuss?

We discuss all compounds that have a legitimate scientific literature and where patients are actively seeking information. We do not withhold educational content because a compound is controversial — but we do frame that content accurately, including regulatory status, evidence limitations, and the populations for whom a compound may be contraindicated. Our goal is informed patients who bring better questions to their clinical consultations.

Can I start a peptide protocol based on reading this library?

No. This library is educational only. Starting any peptide protocol requires a clinical evaluation by a licensed prescribing clinician who reviews your complete medical history, current medications, relevant lab values, and clinical goals. Prescriptions are issued at the sole discretion of the prescribing clinician. Not every compound is appropriate for every patient, and not every compound is available in every state.

Are these pages updated when regulations change?

Yes. Regulatory status pages include a last-reviewed date and are updated when FDA guidance, advisory committee decisions, or compounding rules change. The July 2026 FDA Pharmacy Compounding Advisory Committee meeting is expected to produce significant updates to BPC-157 and TB-500 pages.

Peptide Library — Mechanism, Evidence & What's Real

What this hub is

Education built around honest evidence, not hype.

Peptide medicine is one of the most promising and most misrepresented areas of modern health. Marketing tends to overstate what compounds can do; skeptics tend to dismiss the field entirely. This library tries to do something harder: explain the actual mechanism, grade the actual evidence, and note the actual regulatory status for each compound — so you arrive at a clinical consultation with a useful foundation.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide are the most clinically validated peptide-class medications in recent pharmacology. GLP-1 agonists mimic the gut's natural satiety signal — with RCT evidence showing 15–21% average body weight reduction and a demonstrated 20% reduction in major cardiovascular events (SELECT trial, PMID: 37952131). Regulatory status: FDA-approved for diabetes and obesity; compounding under 503A now restricted to documented individualized patient need following shortage resolution.

Read the Full GLP-1 Page

GH Secretagogues

CJC-1295, ipamorelin, sermorelin, tesamorelin, and MK-677 stimulate the pituitary to release endogenous growth hormone — preserving pulsatility and feedback regulation rather than bypassing it. Tesamorelin carries the strongest evidence (FDA-approved Phase 3 RCT data, PMID: 20554713). CJC-1295 and ipamorelin have Phase 2 pharmacology data and limited human RCTs. The FDA PCAC meeting scheduled for July 23–24, 2026 may affect compounding availability.

Read the Full GH Secretagogues Page

BPC-157

Body Protection Compound-157 is a synthetic pentadecapeptide with compelling preclinical evidence in tendon, ligament, muscle, and gastrointestinal healing across dozens of animal studies. No completed Phase 2 or Phase 3 human RCTs exist. A 2025 systematic review found 35 preclinical studies and 1 clinical case series. Regulatory status: not FDA-approved; subject to review at the July 23, 2026 FDA PCAC meeting for potential 503A bulks list consideration.

Read the Full BPC-157 Page

TB-500 / Thymosin Beta-4

Thymosin Beta-4 is a naturally occurring 43-amino acid peptide that regulates actin dynamics — the cellular machinery underlying tissue repair. TB-500 is the synthetic active fragment. Preclinical data support roles in wound healing, angiogenesis, cardiac repair, and anti-fibrosis. Topical Tβ4 (RGN-259) has reached Phase 2 clinical trials for corneal healing. Systemic human RCTs are absent. Also under consideration at the July 2026 FDA PCAC meeting.

Read the Full TB-500 Page

Our editorial standard

How we evaluate and present evidence.

Not all evidence is equal. We use a standard hierarchy — and we state it explicitly on every compound page — because conflating an RCT with a rat study is how medical misinformation spreads.

Level I — RCTs & Meta-Analyses

Multi-center randomized controlled trials and systematic meta-analyses represent the highest-quality evidence. GLP-1 agonists (STEP, SURMOUNT, SELECT trials) and tesamorelin (Phase 3 pooled analysis) carry this designation.

Level II — Controlled Studies

Single-center RCTs, well-designed controlled studies, and dose-escalation trials in humans. CJC-1295's phase 2 pharmacokinetic trial (PMID: 17018654) and MK-677's elderly RCT (PMID: 8954023) fall here.

Level III — Observational

Cohort studies, case-control designs, retrospective series. One retrospective 12-patient case series exists for BPC-157 in chronic knee pain — the only published clinical data for that compound.

Level IV–V — Preclinical Only

Animal studies (rodent models, swine, equine) and in-vitro mechanistic research. BPC-157 and TB-500 are predominantly at this level. We note this clearly, because biologically plausible is not the same as clinically proven.

Regulatory Accuracy

FDA approval status, 503A compounding legality, WADA prohibited-substance status, and relevant advisory committee timelines are included on every page and updated when guidance changes.

Compliance Language

All content uses "may support," "evidence suggests," and "discuss with your clinician" framing. We never write "will cure," "proven to treat," or "FDA-approved for" off-label uses. Medical decisions rest with licensed clinicians.

FAQ

Questions patients ask before they explore the library.

Start here if you're new to peptide medicine or want to understand how this hub approaches evidence and safety.

What exactly is a peptide?

Peptides are short chains of amino acids that act as biological signaling molecules. They regulate hormone secretion, appetite, tissue repair, inflammation, and immune function. In telehealth medicine, synthetic peptides mimic or amplify these natural signals in targeted ways. The body naturally produces thousands of peptides; therapeutic peptides are synthetic versions designed to produce specific clinical effects.

Are any of these peptides FDA-approved?

Yes — but the approved indications vary significantly by compound. Semaglutide and tirzepatide (GLP-1 agonists) are FDA-approved for type 2 diabetes and obesity management. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. BPC-157 and TB-500 are not FDA-approved for any indication. Each compound page lists regulatory status explicitly.

How do I know if a peptide is right for me?

You don't determine this from reading a library — a licensed clinician does, after reviewing your complete medical history, current medications, relevant lab values, and health goals. This hub gives you a science-literate foundation for that conversation. Prescriptions are issued at the sole discretion of the prescribing clinician.

What does "compounded" mean?

Compounded medications are prepared by licensed pharmacies for individual patients under a specific prescription. They are regulated by state pharmacy boards and must meet USP sterility and quality standards, but they do not go through FDA's pre-market drug approval process. Compounding legality varies by compound — GLP-1 agonists, for example, have significant restrictions as of 2026 following shortage resolution.

Why do so many of these compounds lack human trial data?

Clinical trials are expensive — typically $50M to $1B+ for a full Phase 2/3 program. Peptides that occur naturally or cannot be broadly patented offer limited commercial incentive for pharmaceutical companies to fund trials. This creates a research gap: biologically compelling compounds with extensive preclinical evidence but no human RCT validation. We note this gap honestly for every compound where it applies.

What is the July 2026 FDA PCAC meeting?

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to evaluate whether several peptides — including BPC-157 and TB-500 — should be added to the 503A bulk drug substances list. A positive recommendation could open a legal compounding pathway. Pages for compounds under review will be updated following the meeting with actual outcomes.

Informational only. Content on this page is for informational purposes and does not constitute medical advice. All prescriptions are issued at the sole discretion of the prescribing clinician. Peptide compounds are prescribed for licensed therapeutic indications only. Not all compounds are available in all states. Results vary.

Ready to talk to a clinician?

Knowledge is the first step. Clinical evaluation is the next one.

Start your intake and connect with a licensed clinician who can review whether a peptide protocol aligns with your health history and goals.

Start Your Intake Explore by Goal

Peptides — Mechanism, Evidence, and What's Real